425: Quanterix Announces Q1 2025 Financial Results, Cost Reduction Plan, and Akoya Biosciences Merger Update

Quanterix reported a 5% decrease in revenue for Q1 2025, alongside announcing a cost reduction plan and providing updates on the Akoya Biosciences merger.

Summary

• Quanterix Corporation announced its financial results for the first quarter ended March 31, 2025.
• Revenue for the quarter was $30.3 million, a 5% decrease compared to $32.1 million in the prior year.
• GAAP gross margin was 54.1%, compared to 57.8% in the prior year, while adjusted gross margin was 49.7% compared to 51.2% in the prior year.
• The company reported a net loss of $20.5 million, compared to a net loss of $11.2 million in the prior year.
• Quanterix ended the quarter with $269.5 million in cash, cash equivalents, marketable securities, and restricted cash.
• Adjusted cash burn for the quarter was $9.0 million, compared to $19.4 million in the prior year, after excluding $13.2 million in expenses related to the EMISSION acquisition, Akoya deal expenses, and the company's previous restatement.
• The company is implementing cost reduction initiatives to achieve $30 million in annual savings and aims to generate positive cash flow by 2026 with a cash balance exceeding $100 million.
• For 2025, Quanterix expects revenues in the range of $120 million to $130 million, representing a year-over-year revenue decline of 5% to 13%.
• The company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million.
• The merger agreement with Akoya Biosciences was amended, reducing the equity value of the transaction by 67% and increasing Quanterix shareholder ownership from 70% to 84% post-closing, with the transaction expected to close in June 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is taking proactive steps to reduce costs and streamline operations, the revenue decline and net loss indicate challenges. The amended merger agreement and cost reduction plan are positive, but the overall financial performance is mixed.

Positives

• Quanterix is implementing cost reduction initiatives to achieve $30 million in annual savings.
• The company aims to generate positive cash flow by 2026 with a cash balance exceeding $100 million.
• Adjusted cash burn in Q1 2025 decreased to $9.0 million compared to $19.4 million in the prior year.
• ARUP Laboratories will offer a pTau217 blood test for Alzheimer's disease using the Quanterix platform.
• Quanterix launched a new dried blood spot (DBS) extraction kit to expand access to high-sensitivity testing.
• The Simoa ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide.

Negatives

• Quanterix's Q1 2025 revenue decreased by 5% year-over-year to $30.3 million.
• The company reported a net loss of $20.5 million for Q1 2025, compared to a net loss of $11.2 million in the prior year.
• The company expects 2025 revenues to be in the range of $120 million to $130 million, a year-over-year decline of 5% to 13%.

Risks

• The company faces risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs.
• There are risks that Quanterix may not realize the expected benefits of its cost reduction actions.
• The company faces risks associated with the anticipated timing for launch of, and features of, Quanterixs next-generation instrument, Simoa ONE.
• There are risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc..
• Quanterixs estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• The company faces risks related to the restatement of Quanterixs consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• There are risks related to Quanterixs ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation.
• Quanterixs ability to realize the intended benefits of its assay redevelopment program is a risk.
• The company faces risks related to its ability to retain and expand its customer base and achieve sufficient market acceptance of its products.
• The merger with Akoya Biosciences carries risks, including the possibility of termination, failure to obtain necessary approvals, failure to realize anticipated benefits, increased expenses, diversion of management attention, and potential adverse reactions or changes to business or employee relationships.

Future Outlook

Quanterix anticipates 2025 revenues to be in the range of $120 million to $130 million, representing a year-over-year decline of 5% to 13%. The company expects GAAP gross margin to be in the range of 55% to 59%, and adjusted gross margin (non-GAAP) in the range of 50% to 54%. Finally, the Company anticipates 2025 adjusted cash burn to be approximately $35.0 million to $45.0 million. The company aims to generate positive cash flow by 2026 with a cash balance exceeding $100 million.

Management Comments

• Masoud Toloue, CEO of Quanterix, stated that the company remains committed to keeping the innovation engine moving forward despite market resource constraints.
• Toloue highlighted the compatibility of Simoa ONE assay kits with existing flow cytometers, reducing the need for capital equipment purchases.
• Toloue mentioned that the company is proactively positioning itself for long-term success and is taking a disciplined approach to guidance and implementing targeted cost reductions.
• Toloue noted that these actions strengthen the path to generate positive cash flow by 2026 and help streamline the integration with Akoya Biosciences.

Industry Context

Quanterix is operating in a market facing resource constraints, impacting scientific progress. The company's focus on democratizing access to ultrasensitive biomarker detection and cost reduction initiatives aligns with the need for efficient and accessible research tools. The merger with Akoya Biosciences is likely aimed at expanding the company's offerings and market reach in the biomarker analysis space.

Comparison to Industry Standards

• Quanterix's revenue decline of 5% is noticably worse than companies such as Bio-Techne which is expecting growth of 10% in 2025.
• Quanterix's gross margin of 54.1% is lower than industry leaders such as Illumina, which typically reports gross margins above 70%.
• The adjusted cash burn of $9.0 million is better than companies such as Pacific Biosciences which is burning over $50 million per quarter.
• The cost reduction plan to save $30 million annually is similar to actions taken by other companies in the life sciences sector to improve profitability and cash flow.

Stakeholder Impact

• Shareholders will be impacted by the revenue decline and net loss, but may benefit from the cost reduction initiatives and the amended merger agreement.
• Employees will be affected by the reduction in force, which is expected to be substantially completed by the end of the second quarter of 2025.
• Customers may benefit from the expanded Simoa assay portfolio and the compatibility of Simoa ONE assay kits with existing flow cytometers.
• Suppliers may be impacted by the cost reduction initiatives, which include a reduction in other costs.

Next Steps

• Complete the merger with Akoya Biosciences, expected in June 2025.
• Implement cost reduction initiatives to achieve $30 million in annual savings.
• Launch the next-generation instrument, Simoa ONE.
• Continue to expand the Simoa assay portfolio with new applications and kits.
• Focus on retaining and expanding the customer base.

Key Dates

Keywords

Quanterix, financial results, Q1 2025, revenue, cost reduction, Akoya Biosciences, merger, biomarker detection, Simoa, cash burn